Abstract
Peptides deriving from tumor-associated antigens and recognized by patient T cells have been firstly defined in the early 90's, and then used as vaccine in animal models and in cancer patients. Early trials showed a variable, often even high frequency of patients developing peptide-specific T-cell mediated immune response usually accompanied by a lower frequency of clinical response. Modified, long peptides could be synthesized with a higher in vitro binding to the corresponding HLA allele that only seldom translated into a clear improvement in the tumor response. However, we show here that more recent studies of multipeptide-based vaccines resulted in a higher and more robust T cell response causing also a more effective clinical response particularly in melanoma and prostate cancer patients. In this article, we also used some of the recent patents describing different inventions related to pre-clinical and clinical aspects of peptide based vaccines against human solid tumors.
Keywords: Peptides, tumor antigens, vaccination, clinical response, tumor-associated antigens (TAAs), melanoma antigen (MAGE), HLA haplotype, CTL epitope, HLA receptors, high-throughput receptorligand assays, mass spectrometry, cancer-testis (CT), HLA-A2, peptide-based anti-cancer vaccines, peripheral blood mononuclear cells (PBMCs)
Recent Patents on Biotechnology
Title: Pre-Clinical and Clinical Aspects of Peptide-based Vaccine Against Human Solid Tumors
Volume: 5 Issue: 2
Author(s): Seyed Amir Jalali and Giorgio Parmiani
Affiliation:
Keywords: Peptides, tumor antigens, vaccination, clinical response, tumor-associated antigens (TAAs), melanoma antigen (MAGE), HLA haplotype, CTL epitope, HLA receptors, high-throughput receptorligand assays, mass spectrometry, cancer-testis (CT), HLA-A2, peptide-based anti-cancer vaccines, peripheral blood mononuclear cells (PBMCs)
Abstract: Peptides deriving from tumor-associated antigens and recognized by patient T cells have been firstly defined in the early 90's, and then used as vaccine in animal models and in cancer patients. Early trials showed a variable, often even high frequency of patients developing peptide-specific T-cell mediated immune response usually accompanied by a lower frequency of clinical response. Modified, long peptides could be synthesized with a higher in vitro binding to the corresponding HLA allele that only seldom translated into a clear improvement in the tumor response. However, we show here that more recent studies of multipeptide-based vaccines resulted in a higher and more robust T cell response causing also a more effective clinical response particularly in melanoma and prostate cancer patients. In this article, we also used some of the recent patents describing different inventions related to pre-clinical and clinical aspects of peptide based vaccines against human solid tumors.
Export Options
About this article
Cite this article as:
Amir Jalali Seyed and Parmiani Giorgio, Pre-Clinical and Clinical Aspects of Peptide-based Vaccine Against Human Solid Tumors, Recent Patents on Biotechnology 2011; 5 (2) . https://dx.doi.org/10.2174/187220811796365716
DOI https://dx.doi.org/10.2174/187220811796365716 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |
Call for Papers in Thematic Issues
Advancements in Plant Genetics and Genomics
This thematic issue will highlight cutting-edge innovations and recent patents across the breadth of plant genetics and genomics. Key topics will include advanced breeding techniques, omics-based approaches, gene editing, trait discovery, and translational applications for crop improvement. Renowned researchers from leading institutions worldwide will provide state-of-the-art insights and future perspectives ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Vitamins in Human Health and Nutrition: Sources and Morbidity
Current Nutrition & Food Science Cell Death: Tipping the Balance of Autoimmunity and Tissue Repair
Current Pharmaceutical Design Recent Advances of MEK Inhibitors and Their Clinical Progress
Current Topics in Medicinal Chemistry Recent Developments in Nanomedicines for Management of Various Health Issues Via Metabolism and Physico-Chemical Properties
Current Drug Metabolism Anticancer α-Helical Peptides and Structure / Function Relationships Underpinning Their Interactions with Tumour Cell Membranes
Current Protein & Peptide Science The Synthesis and Use of Boronated Amino Acids for Boron Neutron Capture Therapy
Anti-Cancer Agents in Medicinal Chemistry The Influence of Host Factors on the Prognosis of Breast Cancer: Stroma and Immune Cell Components as Cancer Biomarkers
Current Cancer Drug Targets Anticancer Activity of the Bioreductive and Non-Bioreductive Zerumbone Derivatives
Letters in Drug Design & Discovery Environmental Chemicals and Breast Cancer Risk – A Structural Chemistry Perspective
Current Medicinal Chemistry Cardiovascular Complications of Sleep Disorders: A Better Night’s Sleep for a Healthier Heart / From Bench to Bedside
Current Vascular Pharmacology Role of Plasmacytoid Dendritic Cells in Lung-Associated Inflammation
Recent Patents on Inflammation & Allergy Drug Discovery Aberrant Activation of Arachidonic Acid and Eicosanoid Pathways-Targets for Treating Prostate Cancer
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Inhibitors of the Sphingosine Kinase Pathway as Potential Therapeutics
Current Cancer Drug Targets Applications of Nanomaterials for Cancer Treatment: Recent Patents Review
Recent Patents on Nanomedicine Outcome Measures Following Sonodynamic Photodynamic Therapy – A Case Series
Current Drug Therapy Moving to the Rhythm with Clock (Circadian) Genes, Autophagy, mTOR, and SIRT1 in Degenerative Disease and Cancer
Current Neurovascular Research Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview
Current Drug Safety Surgical Options for Management of Malignant Pleural Mesothelioma in the Current Era
Current Respiratory Medicine Reviews Anti-cancer Potential of Phyto-alkaloids: A Prospective Review
Current Cancer Therapy Reviews IGF Signaling Pathway as a Selective Target of Familial Breast Cancer Therapy
Current Molecular Medicine